- Home
- MDCX vs CGTX Comparison
MDCX vs CGTX Comparison
Compare MDCX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | CGTX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 94.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDCX | CGTX |
|---|---|---|
| Price | $0.50 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $23.50 | $3.33 |
| AVG Volume (30 Days) | ★ 8.2M | 583.8K |
| Earning Date | 03-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.22 |
| 52 Week High | $8.90 | $3.83 |
Technical Indicators
Market Signals| Indicator | MDCX | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 44.89 |
| Support Level | $0.37 | $1.00 |
| Resistance Level | $1.43 | $1.19 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 9.53 | 30.56 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.